Clinical Trials Browser

NCT07261683 2025-12-19

Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

Phase 2 Recruiting

20 enrolled

Gynecologic

Ovarian Neoplasms

NCT06791460 2025-03-18

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Phase 2/3 Recruiting

296 enrolled

Gynecologic

Ovarian Cancer Recurrent

NCT06534762 2024-08-02

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

Phase 2 Recruiting

260 enrolled

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell, Dendritic Cell Sarcoma, Interdigitating, Triple Negative Breast Neoplasms

NCT05779514 2023-03-22

Effect of Mirabegron on Promoting Brown Adipose Tissue Activation

Phase NA Unknown

20 enrolled

Tumor-Agnostic

Neoplasms

NCT03600766 2019-09-04

Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study

Phase 2 Unknown

50 enrolled

Genitourinary

Erectile Dysfunction, Prostatic Hyperplasia, Prostatic Neoplasms

NCT02311569 2019-05-15

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Phase 2 Completed

39 enrolled

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis